Yuhan Corp
KRX:000100

Watchlist Manager
Yuhan Corp Logo
Yuhan Corp
KRX:000100
Watchlist
Price: 104 700 KRW -1.51% Market Closed
Market Cap: 8.5T KRW

EV/EBIT
Enterprise Value to EBIT

127.1
Current
94.6
Median
16.2
Industry
Higher than median
Higher than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
127.1
=
Enterprise Value
7.7T KRW
/
EBIT
60.7B KRW
Market Cap EV/EBIT
KR
Yuhan Corp
KRX:000100
7.7T KRW 127.1
US
Eli Lilly and Co
NYSE:LLY
749.9B USD 39.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 17 702.3
US
Johnson & Johnson
NYSE:JNJ
366.6B USD 16.1
DK
Novo Nordisk A/S
CSE:NOVO B
2.2T DKK 16.4
CH
Roche Holding AG
SIX:ROG
208.1B CHF 11
CH
Novartis AG
SIX:NOVN
187.5B CHF 14.1
UK
AstraZeneca PLC
LSE:AZN
165.3B GBP 197.6
US
Merck & Co Inc
NYSE:MRK
196.9B USD 10.2
IE
Endo International PLC
LSE:0Y5F
163.5B USD 655.3
US
Pfizer Inc
NYSE:PFE
136B USD 10.5
EBIT Growth EV/EBIT to Growth
KR
Yuhan Corp
KRX:000100
Average EV/EBIT: 1 709.1
127.1
64%
2
US
Eli Lilly and Co
NYSE:LLY
39.6
32%
1.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
16.1
13%
1.2
DK
Novo Nordisk A/S
CSE:NOVO B
16.4
14%
1.2
CH
Roche Holding AG
SIX:ROG
11
6%
1.8
CH
Novartis AG
SIX:NOVN
14.1
10%
1.4
UK
AstraZeneca PLC
LSE:AZN
197.6
23%
8.6
US
Merck & Co Inc
NYSE:MRK
10.2
11%
0.9
IE
E
Endo International PLC
LSE:0Y5F
655.3
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.5
10%
1

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
64.2
2-Years Forward
EV/EBIT
37.8
3-Years Forward
EV/EBIT
31.9